Physician profile
Caroline Dsouza
NPI 1205099678
$5,715.07
in general payments reported to CMS, 2019-2025
27 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $189 · 2021: $979 · 2022: $1,075 · 2023: $450 · 2024: $749 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.07 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $923.18 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Novartis Pharmaceuticals Corporation | $792.05 | 2019-2025 | |
| Amgen INC. | $689.12 | 2019-2025 | Enbrel, Otezla, Otezla |
| Glaxosmithkline, LLC. | $520.32 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $389.49 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $385.29 | 2019-2024 | Taltz |
| Janssen Biotech, INC. | $377.73 | 2019-2025 | Tremfya |
| Radius Health, INC. | $194.17 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $185.21 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $165.10 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $159.72 | 2022-2025 | Lupkynis |
| Pfizer INC. | $130.29 | 2019-2024 | |
| Genentech USA, INC. | $121.93 | 2019-2024 | Actemra |
| Alexion Pharmaceuticals, INC. | $109.99 | 2019-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $81.31 | 2021-2025 | Saphnelo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.29 | 2022-2025 | Orencia |
| Horizon Therapeutics Plc | $58.47 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $56.24 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $54.48 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $50.89 | 2025 | |
| Globus Medical, INC. | $42.30 | 2025 | Senza |
| Gilead Sciences, INC. | $35.82 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $33.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.26 | 2019 | |
| Sobi, INC | $18.86 | 2025 | |
| Sandoz INC. | $18.23 | 2023 | Hyrimoz |
| Genzyme Corporation | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Dsouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.